Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease Napa, Calif., July 17, 2023 – Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages […]